Results 61 to 70 of about 236,151 (302)

A Single-Step Immunocapture Assay to Quantify HCC Exosomes Using the Highly Sensitive Fluorescence Nanoparticle-Tracking Analysis

open access: yesJournal of Hepatocellular Carcinoma, 2023
Ali Riza Koksal,1 Nergiz Ekmen,2 Yucel Aydin,2 Kelley Nunez,3 Tyler Sandow,4 Molly Delk,2 Martin Moehlen,2 Paul Thevenot,3 Ari Cohen,3,5 Srikanta Dash1,2,6 1Department of Pathology and Laboratory Medicine, Tulane University Health Sciences Center, New ...
Koksal AR   +9 more
doaj  

Cip2a Mediates Effects of Bortezomib on Phospho-Akt and Apoptosis in Hepatocellular Carcinoma Cells

open access: yes, 2011
Previously, we reported that Akt inactivation determines the sensitivity of hepatocellular carcinoma (HCC) cells to bortezomib. In this study, we report that cancerous inhibitor of protein phosphatase 2A (CIP2A), a cellular inhibitor of protein ...
陳昆鋒;林育靖;陳培哲;鄭安理   +1 more
core   +1 more source

Multifunctional Neutrophil Nanovesicles Induce Remodeling of Tumor Immune Microenvironment and Synergistic Multimodal Tumor Therapy

open access: yesAdvanced Functional Materials, EarlyView.
Schematic illustration of the engineered RN@FDT for multimodal tumor therapy. a) Fabrication of FD&DOX/TFA‐loaded RGD‐NNV (RN@FDT) and the light‐triggered disassemble of RN@FDT. b) After internalized by tumor cells, RN@FDT are disintegrated under NIR‐II laser irradiation to boost PTT and induce cell apoptosis.
Jiahui Zhang   +16 more
wiley   +1 more source

Preliminary results of retrospective analysis Atezolizumab and Bevacizumab in first-line therapy of advanced HCC

open access: yesМедицинский совет, 2021
Introduction. HCC is a challenge for clinical oncology. 1-year mortality for advanced HCC accounts for 66% in theRussian Federation. The results obtained in the combined Atezolizumab and Bevacizumab therapy in the advanced HCC cases are reported ...
I. А. Dzhanyan   +2 more
doaj   +1 more source

Serum Exosome-Derived piRNAs Could Be Promising Biomarkers for HCC Diagnosis

open access: yes, 2023
Tao Rui,1,2 Kai Wang,1,2 Aizhai Xiang,1 Jufeng Guo,1 Ning Tang,1 Xin Jin,1 Yimou Lin,3 Jian Liu,1 Xiaobing Zhang1,2 1Department of Surgery, Affiliated Hangzhou First People’s Hospital, Zhejiang University School of Medicine, Hangzhou, 310003, People’s ...
Rui T   +8 more
core  

Bioengineered Exosome‐Loaded Immunomodulatory Bioadhesive Spray Reverses Liver Fibrosis and Metabolic Dysfunction That Triggers Beneficial Gut‐Liver Crosstalk in Chronic Fatty Liver Disease

open access: yesAdvanced Science, EarlyView.
Umbilical cord stem cell‐derived exosomes encapsulated in an immunomodulatory bioadhesive hydrogel spray enable localized therapy, sustained vesicle delivery, macrophage polarization, suppress systemic inflammation, and mitigate glucose and insulin homeostasis impairments in MAFLD.
Triya Saha   +4 more
wiley   +1 more source

Systematic Position Mapping of Split CRISPR‐Cas12a Activators Enables Highly Sensitive miRNA Detection and Cancer Cell Stratification

open access: yesAdvanced Science, EarlyView.
ABSTRACT Amplification‐free Cas12a diagnostics with split crRNA enable rapid and programmable target recognition, yet insufficient understanding of DNA activator architecture prevents predictable control over trans‐cleavage activity and sensitivity. Here we systematically map over 200 split DNA activator configurations by introducing nicks at every ...
Xiaoyan Tang   +8 more
wiley   +1 more source

Expression of Mina53 and CBX8 in Hepatocellular Carcinoma and Their Correlation with Clinicopathological Features and Prognosis

open access: yesZhongliu Fangzhi Yanjiu, 2020
Objective To investigate the expressions of Mina53 and CBX8 in hepatocellular carcinoma (HCC), and to analyze their correlation with the clinicopathological features and prognosis of HCC patients.
YE Dongxue   +5 more
doaj   +1 more source

Macrophages as a source of fibrosis biomarkers for non-alcoholic fatty liver disease

open access: yesImmunological Medicine, 2021
Non-alcoholic fatty liver disease/steatohepatitis (NAFLD/NASH) are becoming major liver diseases worldwide. Liver fibrosis and cirrhosis are among the most significant risk factors of hepatocellular carcinoma (HCC) and associated with the long-term ...
Sachiyo Yoshio, Tatsuya Kanto
doaj   +1 more source

Nine months to progression using fourth-line liposomally encapsulated paclitaxel against hepatocellular carcinoma [PDF]

open access: yes, 2008
Background: Hepatocellular carcinoma (HCC) is the third most common cause of cancer deaths. Difficulties to diagnose HCC at early stages remain the major obstacle to curative (surgical) therapy. Therapy in advanced stages has to be considered palliative.
Forstpointner, Roswitha   +6 more
core   +1 more source

Home - About - Disclaimer - Privacy